Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retaject
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Retaject is a selectable, multi-dose injectable pen formulation of retatrutide (LY-3437943) developed and sold by GLP North for research purposes in Canada. The active ingredient, retatrutide, is an experimental synthetic peptide originally developed by Eli Lilly and Company. It acts as a triple hormone receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors to regulate appetite, glucose control, and energy balance. Retaject is primarily investigated for the treatment of obesity and metabolic conditions such as type 2 diabetes.
- Brand names
- Retaject
02
Targets
Beyond the preview
Go deeper on Retaject.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Retaject.